DOCSLIB.ORG

Psilocin (Psi} and Dimethyltryptahin£ (Dmt)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Psilocin (Psi} and Dimethyltryptahin£ (Dmt) Federation Proceedings 3/7, No. 3, (1978) 273 LSD-LIME HALLUCINOGENS IN THE DOG: VALIDATION STUDIES WITH ACUT_ AND CNSONXC I_rr_P.ACTIONS S_.EN A_-TZTP-AHYnROCANNA - MESCALINE (MES), PSILOCIN (PSI} AND DIMETHYLTRYPTAHIN£ (DMT). BINOL (_9-THC) _O PE_roBARBIT^B IN _ PIGEON. D._. McMillan, DR Vs..m]* and W.R, Marttn. NIDA Addiction Research Center. _eparunent of Pharmacology, School of Medicine, Univer$it-y_ Lexington. Ky. 40583, -- North Carollnar C_lapel Hill, N.C. 27S14. Single dose (t.v.) effects of MES(4 mg/kg), PSI (0.05 mg/ Pigeon= were trained to peck a response key to obtain kg) a,d DMT (0,3 mg/kg) were evaluated tn nontolerant and LSD food under a multiple fixed-ratio 30 response, fixed-interval tolerantchronicspinaldogs, AppetitesupgresSa.teffectsof 5-mln (mull FR 30 FI 5) schedule of relnforcement, Intra- MES and PSI were assessedIn intactdogs. Inn0ntolerantdog_ muscularIn_ectlonsof pentobarbltalproduceddose-dependent MES, PSI and DMT speclflcally resembled LSD (15 uglkg) and not decreases in the rate of reapondlng under both schedule eom- d-amphetamine (A) (2 _/k 9) with respect to thelr physiologic ponents. A dQila of Ag-TNC (l.O mg/kg) that produced no oon- and behaviora_ effects. LSD tolerant dogs (30 P9 LSD/kg/day) slstent effect when given alone, greatly potentiated the were cross tolerant to PSI and MES but not A. Partial cross cete-deereaalng effects of pentoherbital. Subsequently, the toleranceto DMT developedas itsmydrlaslsand facil_atlve pigeons w_re made tolerant to the effects of _9-TBC by plying effect on the flexor reflex were not slgnlflcantly reduced, lO mg/kg injentionB after the test sessions onM ondaye and These results are In agreement wlth clinical pharmacologlc Wednesdays and 20 mg/k9 injections after the test session on studies (Psychopharmac010gia2;147, 1961; 3:1, 1962; 3:219, Fridays for 4 weeks. Birds tolerant to Am-TaG were cross 1962; 5:217, 1964). LSD, MES and PSI administered s.c. sup- tolerant to penbobarbital, as demonstrated by a shift in the pressed food intake _n dog and produced parallel dose-response dose-affect curve that was approximately two-fold. Further- curves. However. their slopes were significantly less than more, in birds tolerant to 6_-THC the 1,0 mg/kg dose of A9. that of A. LSD, MES and PSI did not completely abolish food TBC no longer potentiated the rate-decreasing effect ofpento- intake as did A. In conclusion MES, PSI and DMT are pharma- barbital. Is fact_ these birds also showed an approximately cologlcally equivalent to LSD in the do9 as they are i, man htwlgho-foldec dosshes,ift Tofhus,the thpentobe acutarbitale combinationdose-effeofct a scmuarllve dtowarose do_ su_gesttn 9 that the dog can be used to assess c(xnpounds for _9-_c shifts the pentobarbital dose-affect Curve downward and tSD-llke activity, to the left, but in birds tolerant to 69-THC the pentobarbitai dose-effect Curve shifts to the right, regardless of whether or not the small dose of _9-THC is present. (Supported by NIDA Grant #DA-00570.) _8 _HARMACOLOGY _29 PH_SMACOLOGY THE BIPHA_IC EFFECT OF _9-TETRAHYDROCANNABINOL (Ag-THC) ON EFt:Eel'S OF MET}I/_IPHETAMINE ANP HALOPERIPOI. ON FINE M_I'OR CON- THE UPTAKE OF CATECHOLAMINES INTO SYNAPTO_OMES FROM RAT TROL BEFORE AND AFTEII REPEATED I_IECTfONS OF HETIbgWIIET_HNE, HYPOTHALAMUS AND CORPUS STRIATUM..M K. Pode_.......dsr t ....W.L. Deweez_- C.E. Joh_C_..Schustor, T. Ai_ner* and L.S. Seiden, a.d L.S. Harris. Dept. of Pharmacol., Mad. Col. of Vs., _f Chicago, Chicago, Ill. 6(_37 VS. Cotmm. Univ., Richmond, VA 23298. Three rhesus monkeys were trained fo extend tbeir arm and Concentrations of Ag-THC ranging from O.Ol to 100 uM were hold a lever with between 25 and 40 g of force for 3 or 5 con- tested for their effect on the uptake of 3H-dopamlne iDA) tinuous sac. Following each response of correct _brce and and 3R-noreplnephrlne (NE) Into synaptosomal preparatlons duration_ 1,5 ml of water was delivered. Sessions were con- _ao]ated from rat corpus stristum and hypothalamus. Concen- tinued uetil 50 water deliveries or 30 min had occurred. When tratlons of 0,05. 0.1 and 0.2 _M &9-THC caused a elgttlficaet rate and _atter_ of responding became _table, single i.m. in- increase in the _ptake of OK in the corpus strlatum (2&,34 and jections of either methamphetamine (HA) (O.O6-0.5 mR/kR) or 33% respectively_ and at O.I and 0.2 UM to the hypothalemua ha loperidol (HI (0.O1-0.08 m_/kg) were give_% 20 m_n before the (28 and 25Z respectively). At higher eoa%centrst_ona (IO _H session. Daily sessions were then terminated. Animals were and I00 BM) &9-THe caused a sl_Ifieant reduction in the given 2 dally i.m. injections of )_A for a period of 4 months. uptake of DA into corpus strlatum (35 and 80_ respectively) The dose was gradually increased from 0.5 to 16 mR/kg/in) as a_d hypothalamus (25 and 4BY respectIvely_. Similarly, con- tolerance developed to MAts anorcxigenic effects. Two weeks centrelines of 0.I end 0.2 uM 69-THC caused a aignlflcant following the cos_letion of this regimen, sessions were re- increase in the uptake of NE into the hypothalamus (33 and 2&_ armed. When responding became stable (2 months later), single respectively) and O.I _M hut not 0.2 pM 69-THC increased the injections Of MA and H were given as before, For 2 of the uptake of NE into the corpus strletum (38Z). ConcentratJoas animals, higher doses of MA were required to disrupt respond- of 10 and I00 UH &9-THC signlflcantly decreased the uptake of ing, indicating tolerance. For the third an/mal, there was NE into both hypothalamus and corpus strlatum. Concentrations no change. For both animals given 1|, lower doses d/erupted of O.OI and I uH were Insetlve on the uptake of both DA and NE. responding, indicating increased sensitivity. These c_anges _eee biphas_c effects of 69-q_HC on brain eatecholamines may in responsivity to _ and H are consistent with our prior explain the dual stimulatory-depreseant effects of thls drug findings that the repeated administration of HA produces in mice. (Supported by USPHS grant no. DA-004901. marked irreversible depletion of dopamine in the ni_ro_str}a- tel tract. (Supported by USPI_ NIDA Grants DA-OO2S0, -OO085 and -O00241 390 PHABMACOLOOY _3| PHARMACOLOGY DEIr_LOPHE_IT OF Ct_8 TOLERANCE TO E_RBITAJ_ AND P_NTOBARBIT/L5 DIFEERENTIAL FUNCTIONAL IOLER.aiICE DEVELOPMENT AFTER ADHINIS- IN PATS. Judith A. Richter. In4t*.na U. Med, _h,_ TRA'ItON OF PHENOBaRBItAL [I'B) OR N,N-DIHETIIOXYHETHYL-PB (DB_W) In¢lanaPollm, IN h_202 IN TIIE RAT, L.S. Freer* J.A. Nuite* and B.B. (;allaj_[_, In order to develo_ _n in vltr_mo_el of br&in tolermnce Dept. of Pharmacol,, Georgetown Uni_,, Washington, I_ 20007 to _arblt_rates, we are teetlnK various me%ho_ of a_nls- There is some evidence that despite the sequential metabo- %ration of bsrblgsl (B) a_d Dentob_rbltal (PB) %o r_ts %0 de- lism of the snticonvulsant DMblP (eterobarb) to N-methoxy- velop _n vi-*o CBE to%e_oe. When Inereaslng concentre%ions methyl-PB (N_iP) and PB, less sedation accompanles the use of of B were supplied to rats In thel_ drlnki.K w&tem (Morgan DMMP than equiequivalent doses of PB alone. To _nvestigate e.__t_l,, Life Bet. 20: %93, 19771, br_dn eald pl_sma levels of the possible role of differential tolerance development to PB B gradueO.ly rose over the one month period to 800 nmoles/g following D_P administration, rats were acutely administered and 1_OO nmolee/m.l, respectively. After a test doee of _aB pharmacologically equivslent oral doses of PB or DMMP and l,p. toler_mt rags had at least twice the amo*mt of E u con- sacrificed at the time of loss of fhe righting reflex (LRR). trols in their brains at aw_kenlng. A smaller @tree of in PB _ _@4P were analyzed simultaneously by GLC. Mean brain w_vo. tolerance to PB ha_ been achieved by daily s.c. In- barbiturate levels, determined after acute PB or D_P, of Jecttons of Increasing 8mo_mte of PB In an oil suspension for 41.2 ± 2.6 (PB=IO0%) or 75,8 t 2.4 (PB=80%, MMP=20%} 0g/gm of h-5 days. Peak brain levels of _O nmolee PB/g were found wet weight tissue, respectively, were significantly different. ai'_er the lut injection. After a test doee of H_/_B l,p., To compare tolerance development, a "chronically equivalent" tolerant rata had 1.3-i.5 times ae mush PB ae control eats in dos_nK method (8oisse _ Okamoto, JPET, in press) was adapted their brains at awakening, ffowever _here was no decrease In for rats. After progressively increaslog doses of PB or O_IP the inhibition by PB in vitro of K+-stlmulate_ aeetyleholine were chronica11y (6 days) administered, mean brain barbiturate release from mldbraln ellces from PB-toler_nt rttte scampered levels at LRR of 80,S ± 6,3 (PB=lO0%) or li0.2 t 4.5 (PB=99%, to controls. These results s_ggee% either %ha% • greater _e- _MP=I%) Dg/gm, respectively, showed a sig1%ificant increase tree of CBS tolerance in vlvo manet be achlev_d in nrder to oh- after chronic D_P when compared to chronic PB. The differ- serve %clefs.nee %o this i_vi_l'9," effect, or that the toler- ences between acute _ chronic PB or D_FFiPwere else signifl- anee m_ not be cauae_ by a ehmage in release meeh_ati_ms, cant.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Pharmacovigilance & Clinical Trials
    Penichet KO, Clin Exp Pharmacol 2012, 2:3 http://dx.doi.org/10.4172/2161-1459.S1.005 International Conference and Exhibition on Pharmacovigilance & Clinical Trials October 1-3, 2012 DoubleTree by Hilton Chicago-North Shore, USA A comparison of the toxicity effects of the anticonvulsant eterobarb and phenobarbital in normal human volunteers Penichet KO New York Medical College, USA enewed corporate interest in the anticonvulsant drug eterobarb justified renewed clinical and experimental interest in this Rdrug. The unique and clinically intriguing feature of eterobarb is that while sharing the anticonvulsant properties of other barbiturates, the hypnotic side effects usually associated with barbiturates appear to be absent in animal studies and greatly reduced in clinical trials. This study was designed to compare the hypnotic effects of eterobarb with those of phenobarbital in healthy normal human volunteers using a double-blind, placebo-controlled design. Both clinical and neuropsychological parameters of toxicity were measured, while blood barbiturate levels were monitored to correlate neurobehavioral changes with total barbiturate level. As expected, there is a linear relationship between the degree of toxicity and the barbiturate level, but much higher barbiturate levels were tolerated without toxicity by subjects taking eterobarb. For ethical reasons, subjects were not maintained at high levels of toxicity over the 10-week trial. However, both eterobarb and phenobarbital recipients failed to show significant improved performance on Digits Total, a test of mental flexibility (Digit Symbol Substitution). In addition, phenobarbital recipients showed the only significant decrement of performance on Digits Total, and they failed to improve significantly on Trails-Part A, in which all other groups improved.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Issue #81-92, 1976
    ISSN 0090-1350 LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedical Communications Network No 81 January 197 THE CONTENTS OF THIS PUBLICATION ARE NOT COPYRIGHTED AND MAY BE FREELY REPRODUCED TABLE OF CONTENTS Page Journal Citation Data Bases 2 On-line Technical Notes 2 Proposed Conversion from TSO to TCAM Message Handler As NLM's Teleprocessing Interface 5 Hedges , 9 Responsible Use of On-line Data Bases 11 An Experiment in On-Site Training, Madison, Wisconsin — December 15-19, 1975 12 Tumor Key Errata 14 MEDLINE Trainees at the University of Wisconsin, December 15, 1975 14 New Serials Announcement - December 1975 15 MEDLINE Trainees at NLM, January 12, 1976 17 U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service National Institutes of Health LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN of the Library Component of the Biomedlcal Communications Network JOURNAL CITATION DATA BASES EDITOR Grace H. McCarn Head, MEDLARS Management Section MEDLINE and SDILINS were updated with National Library of Medicine February 1976 citations at NLM and SUNY on 8600 Rockville Pike January 12. The sizes, Index Medicus date Bethesda, Maryland 20014 ranges, and entry date ranges are given (301) 496-6193 TWX: 710-824-9616 below: ASSISTANT EDITOR P.E. Pothier MEDLINE (Jan 74 - Feb 76) - 486,93? (Entry Dates: 731130 to 760102) TECHNICAL NOTES EDITOR Leonard J. Bahlman SDILINE (Feb 76) - 21,138 (Entry Dates: 751210 to 761012) The LIBRARY NETWORK/MEDLARS TECHNICAL BULLETIN is issued monthly by the Office of the Associate Director for Library Operations. ON-LINE TECHNICAL NOTES PLEASE QUERY THE NLM/ON-LINE NEWS FILES DAILY FOR SPECIAL NOTICES AND MESSAGES Whenever applicable, in the margin beside each Technical Note., users will be referred to the section/page of the NLM On-Line Services Reference Manual which is considered most relevant to the item being discussed (e.g.., Manual II-9) .
    [Show full text]
  • New Antiepileptic Drugs
    TREATMENT OF CHILDREN WITH SEIZURES New antiepileptic drugs ROGER J. PORTER, MD EW medications are the best hope for tens of that could be used to test anticonvulsant activity, the thousands of patients in the United discovery of the antiepileptic effect of bromide and States—and many more worldwide—for phenobarbital was serendipitous. Later, with the devel- control of their epileptic seizures. Only a opment of seizure models, the search for new AEDs was Nfew patients whose disease is currently refractory to based on scientific screening programs. available medications can be considered for surgical The year 1937 marked the beginning of the experi- intervention; other nonmedical therapies such as bio- mental evaluation of promising anticonvulsant chemi- feedback appear to have a similarly limited role. This cals prior to clinical use. Employing a seizure model paper examines a few of the issues related to the based on a new electroshock technique for producing development of new antiepileptic drugs (AEDs) and convulsions in animals,5 Merritt and Putnam6-7 considers some of the data on the most important of screened a group of compounds supplied to them by these new compounds. Current therapy has been re- Parke-Davis and discovered the anticonvulsant proper- viewed in detail elsewhere.1-2 ties of phenytoin, then called diphenylhydantoin. Be- cause phenytoin was well tolerated by laboratory ani- mals, it was subjected to clinical trials in 1938 and EARLY ANTIEPILEPTIC DRUGS marketed that same year. The absence of a sedative effect and the dramatic control of seizures observed In the nineteenth century, bromides were widely when phenytoin was added to barbiturate therapy were used as antiepileptic agents.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • As Novel Anticonvulsants
    DESIGN AND SYNTHESIS OF SOME ARYLOXYARYL SEMICARBAZONES AND RELATED COMPOUNDS AS NOVEL ANTICONVULSANTS A Thesis Submitted to the College of Graduate Studies and Research in Partial fulfillment of the Requirements for the Degree of Doctor of Philosophy in Pharmacy BY Puthucode Ramanan Narayan Spring 1996 @ Copyright Puthucode Ramanan Narayan, 1996. All rights reserved. National Library Bibliothaue nationale du Canada Acquisitions and Acquisitions et Bibliographic Services sewices bibliographiques 395 Wellington Street 395. rue Wellington OttawaON KIAON4 Ottawa ON KIA ON4 Canada Canada Yarrfi vQtmrd&knw Our t% Norre rdfdrente The author has granted a non- L'auteur a accorde une licence non exclusive licence allowing the exclusive pernettant a la National Library of Canada to Bibliotheque nationale du Canada de reproduce, loan, distribute or sell reproduire, prster, distribuer ou copies of this thesis in microform, vendre des copies de cette these sous paper or electronic formats. la fome de microfiche/fihq de reproduction sur papier ou sur format eectronique. The author retains ownership of the L'auteur conserve la propriete du copyright in this thesis. Neither the droit d'auteur qui protege cette these. thesis nor substantial extracts fiom it Ni la these ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent etre imprimes reproduced without the author's ou auh-ement reproduits sans son permission. autorisation. UNIVERSITY OF SASKATCHEWAN College of Graduate Studies and Research SUMMARY OF DISSERTATION Submitted in partial fulffflment of the requirements for the DEGREE OF DOCTOR OF PHILOSOPEW by Puthucode Ramanan Narayan College of Pharmacy and Nutrition University of Saskatchewan Spring 1996 Examining Committee: Dr.
    [Show full text]
  • 1. Pubmed Search Strategy for Barbiturates: ("Schizophrenia"[Mesh
    1. PubMed search strategy for barbiturates: ("Schizophrenia"[Mesh] OR "Schizophrenia, Childhood"[Mesh] OR "Schizotypal Personality Disorder"[Mesh] OR "Psychotic Disorders"[Mesh:NoExp] OR "Paranoid Disorders"[Mesh] OR Delusional Disorder*[tiab] OR Psychotic*[tiab] OR Psychosis[tiab] OR Psychoses[tiab] OR Schizoaffective[tiab] OR "Schizo Affective"[tiab] OR Schizophreniform[tiab] OR Schizotyp*[tiab] or Schizophreni*[tiab] OR "Dementia Praecox"[tiab] OR Paranoi*[tiab] OR "Folie a Deux"[tiab] OR "Folie a Trois"[tiab]) AND ("Barbiturates"[Mesh] OR Allobarbital[tiab] OR "Ammonium Purpurate"[tiab] OR Amobarbital[tiab] OR Amsal[tiab] OR Amylobarbitone[tiab] OR Amylobeta[tiab] OR Amytal[tiab] OR Aprobarbital[tiab] OR Barbamyl[tiab] OR Barbexaclone[tiab] OR Barbit*[tiab] OR Barotal[tiab] OR Benzobarbital[tiab] OR Bomathal[tiab] OR Brallobarbital[tiab] OR Brevimytal[tiab] OR Brevital[tiab] OR Brietal[tiab] OR Bucolome[tiab] OR Butalbital[tiab] OR Butethal[tiab] OR Cyclobarbital[tiab] OR Cyclopentobarbital[tiab] OR Desoxyphenobarbital[tiab] OR Diabutal[tiab] OR Dialuric[tiab] OR Diemal[tiab] OR Diethylmalonylurea[tiab] OR Difebarbamate[tiab] OR Dormileno[tiab] OR Etaminal[tiab] OR Eterobarb[tiab] OR Ethaminal[tiab] OR Ethylbarbit*[tiab] OR Eunoctal[tiab] OR Evipan[tiab] OR "Fali Lepsin"[tiab] OR Febarbamate[tiab] OR Gardenal[tiab] OR Heptabarb[tiab] OR Hexenal[tiab] OR Hexobarbit*[tiab] OR Hydroxyphenobarbital[tiab] OR Hysteps[tiab] OR "Isoamitil Sedante"[tiab] OR Isonal[tiab] OR Liskantin[tiab] OR Luminal[tiab] OR Meballymal[tiab] OR Mebaral[tiab]
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]